
    
      This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel
      group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day to placebo in
      the treatment of patients with relapsing multiple myeloma who received one previous therapy.

      Patients will receive study treatment (masitinib/placebo) with the standard therapy
      (bortezomib and dexamethazone).
    
  